Register now to R3i !
Your Login
Your Password
Confirm Password  
Your Email
R3i editorial
14 October 2016

Prof. Jean Charles Fruchart, Prof. Michel Hermans, Prof. Pierre Amarenco
Remnants linked with diabetic myocardial dysfunction Read more...

Cholesterol-rich remnants are the products of the degradation of very low-density lipoproteins (secreted from the liver) and chylomicrons (secreted from the intestine). Plasma level of remnant cholesterol, a measure of remnant lipoproteins, is highly correlated with circulating levels of triglycerides, a key component of atherogenic dyslipidaemia that is a driver of cardiovascular risk .
Indeed, bearing in mind that the cholesterol content of these remnant lipoproteins is about five times that of low-density lipoprotein cholesterol (LDL-C), perhaps it is not surprising that accumulating evidence from observational, genetic and mechanistic studies shows that elevated levels of remnant cholesterol are causal for atherosclerotic vascular disease.
PCSK9 and Atherosclerosis
Downloadable slidekit
PCSK9 downloadable slidekit
Created by Professors Jean Davignon (Vice-President of the R3i foundation), Jean-Charles Fruchart (President of R3i) and Michel Hermans (R3i General Secretary), the latest downloadable deck of 242 slides discusses the potential role for anti-PCSK9 mAbs in the future management of cardiovascular disease.
landmark study
14 October 2016

Icosapent ethyl (eicosapentaenoic acid ethyl ester) reduces remnant cholesterol: Results from the MARINE and ANCHOR studies Read more...

A growing body of evidence shows that elevated RLP-C levels are associated with increased risk for atherosclerotic cardiovascular disease in high risk patients, even in those on statin treatment,1,2 and makes the case for considering high RLP-C as a contributor to lipid-related residual cardiovascular risk.3-5 ...
focus on...
14 October 2016

Remnant cholesterol and decreased myocardial function in type 2 diabetes Read more...

This report shows that increasing levels of remnant cholesterol and triglycerides (which are makers of remnant cholesterol) are associated with subtle changes in left ventricular systolic function in type 2 diabetes patients, the majority of whom were on statin therapy and had well controlled LDL-C...
recent publication

Hot off the Press: Topline results for GLAGOV with the PCSK9 inhibitor evolocumab look goodRead more...

According to a press release, GLAGOV (GLobal Assessment of Plaque...
recent publication

Dyslipidaemia management in type 2 diabetes still far from optimalRead more...

In the German DIVE (DIabetes Versorgungs-Evaluation) and the DPV (Diabetes-Patienten-Verlaufsdokumentation)...
recent publication

New analysis highlights need for aggressive lipid manaRead more...

This post hoc pooled analysis of three randomized trials of...
recent publication

Peripheral artery disease associated with increased cardiovascular riskRead more...

In this analysis of the PreterAx and DiamicroN modified-release controlled...
recent publication

A link between APOC3, triglycerides and coronary disease via miR-4271 binding?Read more...

Emerging evidence shows that loss-of-function mutations in the gene encoding...
recent publication

SPIRE outcomes studies with bococizumabRead more...

Although statins significantly reduce vascular event rates, lipid-related residual cardiovascular...

What is residual risk ?

Residual risk of vascular events persisting in patients at treatment goals according to current standards of care or failing to meet goals, including risk related to dyslipidemia, high blood pressure, hyperglycemia, systemic inflammation and unhealthy lifestyles.

What is the Initiative ?

The R3i, a worldwide, academic, multidisciplinary non-profit organization, aims to successfully address the excessively high risk of macro- and micro-vascular complications in patients with atherogenic dyslipidemia, characterised by elevated triglycerides and low levels of high-density lipoprotein (HDL) cholesterol and unaddressed by current standards of care.